Diarrhea-predominant, irritable bowel syndrome (IBS-D) is one of the most frequent gastrointestinal disorders seen and is characterized by abdominal pain, loose watery stools, and urgency in the absence of an identifiable inflammatory, structural, or metabolic abnormality. One of the most common and difficult to treat IBS-D groups are those who contract an enteric infection from food poisoning and subsequently develop post-infectious, diarrhea-predominant, irritable bowel syndrome (PI-IBS-D). The mechanism(s) of persistent diarrhea and visceral nociception following resolution of the colitis are unclear and further work is needed to understand its pathophysiology. It puts an enormous financial burden on health care resources and decreases quality of life. Unfortunately, pharmacologic therapies for PI-IBS-D remain limited and unsatisfactory. Therefore, we are focusing on this subpopulation of patients to study the underling mechanism(s) of post-colitis gastrointestinal dysfunction. We now have preliminary data that provides a very strong rationale for the role of Catechol-O- Methyl-Transferase (COMT) and miRNAs leading to GI dysfunction in PI-IBS-D patients. Enteric infections alter gastrointestinal function and visceral nociception leading to PI-IBS-D. We have identified miRNAs in PI-IBS-D patients, modulated by COMT signaling pathways, that target downstream genes in the colonic enteric nervous system which control post-inflammatory regulation of gastrointestinal function and visceral nociception. We hypothesize that miRNAs dysregulate downstream targets following an enteric infection through altered COMT signaling pathways. These new findings suggest that PI-IBS-D involves dysregulation of complex regulatory pathways in which miRNAs interact through downstream targets. Our lab has established techniques to determine inter- and intra-cellular roles of miRNAs in the epigenetic regulation of the expression of their down-stream target genes. These methods include interaction analysis of miRNAs; in vitro transfection of miRNAs; and in vivo injection of miRNAs oligonucleotides. These findings may shed light on the mechanisms of dysregulation of gastrointestinal function in PI-IBS-D patients. This will overcome a critical barrier to progress in the management of patients following enteric infection and colitis?absence of effective treatment interventions and may lead to preventive and/or therapeutic strategies in PI-IBS-D patients that mimic or inhibit the effects of specific miRNAs on target gene expression.
Some patients who develop food poisioning go on to develop chronic diarrhea and abdominal pain after their initial infection of the gut has cleared. The current proposal will investigate the underlying causes of these chronic gastrointestinal symptoms by examining biological factors (neurotransmitters and genes) that modulate the changes in both humans and mice. Knowing the biological basis of these gastrointestinal symptoms should suggest new therapeutic approaches and greatly facilitate development of better drugs for treating these patients.
